# GRN1005 in Non-Small Cell Lung Cancer (NSCLC) Patients With Brain Metastases (GRABM-L)

> **NCT01497665** · PHASE2 · TERMINATED · sponsor: **Angiochem Inc** · enrollment: 16 (actual)

## Conditions studied

- Non-small Cell Lung Cancer (NSCLC) With Brain Metastases

## Interventions

- **DRUG:** GRN1005

## Key facts

- **NCT ID:** NCT01497665
- **Lead sponsor:** Angiochem Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-11
- **Primary completion:** 2013-01
- **Final completion:** 2013-02
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** Slow recruitment
- **Last updated:** 2019-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01497665

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01497665, "GRN1005 in Non-Small Cell Lung Cancer (NSCLC) Patients With Brain Metastases (GRABM-L)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01497665. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*